Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme-Reference-Cited by-同舟云学术

Successful reinstitution of agalsidase beta therapy in Fabry disease patients with previous IgE-antibody or skin-test reactivity to the recombinant enzyme

Published:2008-05 Issue:5 Volume:10 Page:353-358
ISSN:1098-3600
Container-title:Genetics in Medicine
language:en
Short-container-title:Genetics in Medicine

Author:

Bodensteiner David,Scott C. Ronald,Sims Katherine B.,Shepherd Gillian M.,Cintron Rebecca D.,Germain Dominique P.

Publisher

Elsevier BV

Subject

Genetics (clinical)

Reference12 articles.

1. Desnick RJ, Ioannou YA, Eng CM, Alpha-galactosidase A deficiency: Fabry disease. Scriver CR, Beaudet A, Sly W, Valle D, et al., editors. Metabolic and molecular bases of inherited disease, 8th ed. New York: McGraw Hill 2001; 3733–3774.

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabry nephropathy: a treatable cause of chronic kidney disease;Rare Disease and Orphan Drugs Journal;2024-07-11

2. Reducing agalsidase beta infusion time in Fabry patients: low incidence of antibody formation and infusion-associated reactions in an Italian multicenter study;Orphanet Journal of Rare Diseases;2024-02-02

3. Successful Desensitization in a Patient with Fabry Disease with Agalsidase Beta Anaphylaxis: A Rare Case Report;Asthma Allergy Immunology;2023-04-07

4. A Fabry Disease Patient Who Developed Hypersensitivity Reaction against Agalsidase Beta following COVID-19 Infection;Nephron;2022-09-29

5. An expert consensus on practical clinical recommendations and guidance for patients with classic Fabry disease;Molecular Genetics and Metabolism;2022-09